# Use of nMoABs for the Treatment of COVID-19 in Patients With HM.

> **NCT04932967** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 91 (actual)

## Conditions studied

- Covid19
- Hematological Malignancy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04932967
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932967, "Use of nMoABs for the Treatment of COVID-19 in Patients With HM.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04932967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*